News
Stocktwits on MSN13d
Eli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s SoldEli Lilly's experimental obesity therapy bimagrumab drew mixed reactions from Wall Street after the company recently ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...
Zacks Investment Research on MSN5d
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales GrowthWhile Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...
Zacks.com on MSN11d
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...
Estimates for Eli Lilly’s 2025 earnings have declined from $23.06 to $21.95 per share in the past 60 days, and estimates for 2026 earnings have declined from $31.15 to $30.91 over the same ...
Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. ... This Phase II study, published in September 2023, ...
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback